Indicators of well-controlled asthma
Daytime symptoms <2 times/week, nighttime symptoms <2 times/month
Role of sputum culture in COPD exacerbation
None
Diagnosis suggested by TLC <80% of predicted
Restrictive lung disease
Most common middle mediastinal mass
Lymphadenopathy
OSA symptom most responsive to treatment
Daytime sleepiness
Test for exercise-induced bronchoconstriction
Methacholine or exercise bronchial challenge test
Antibiotic class for severe COPD with frequent exacerbations
Macrolide
High-prevalence condition in young patients with DPLD
Connective tissue disease
Most common posterior mediastinal mass
Neurogenic neoplasms
First step in evaluating excessive daytime sleepiness
Actigraphy or sleep diary
Noninvasive tool to quantify eosinophilic airway inflammation
Fractional exhaled nitric oxide test
Emphysema amenable to lung reduction surgery
Upper lobe predominant
Diagnosis suggested by environmental exposure, fever, fatigue, cough
Hypersensitivity pneumonitis
Initial test for cystic fibrosis
Sweat chloride
CPAP treatment alternative for mild/moderate OSA
Oral appliance
Characteristic biomarkers in patients with allergic asthma
Serum eosinophilia, high IgE, elevated fractional exhaled nitric oxide
Possible complication during air travel in asthma or COPD
Pneumothorax
Treatment for severe radiation pneumonitis
Glucocorticoids
Pulmonary infections suggestive of bronchiectasis
Pseudomonas aeruginosa, Aspergillus, non-TB mycobacteria
Systemic sclerosis variant associated with PAH
Limited cutaneous systemic sclerosis
Asthma monotherapy associated with increased mortality
LABA
Test to determine supplemental O2 needs during air travel
Hypoxia altitude simulation testing or 6-minute walk test
Nonmalignant asbestosis–related pulmonary and pleural disease manifestations
Pulmonary fibrosis, pleural effusion, pleural plaques
Empiric antibiotic class for bronchiectasis exacerbation
Fluoroquinolone
Drug treatments for high-altitude pulmonary edema
Nifedipine, PDE-5 inhibitor